Preclinical Data on ARIAD's Oncology Pipeline to Be Presented at the AACR Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new preclinical data on ridaforolimus, its investigational mTOR inhibitor being co-developed with Merck, AP24534, its investigational pan-BCR-ABL inhibitor, and AP26113, its investigational anaplastic lymphoma kinase (ALK) inhibitor, have been accepted for seven presentations, including two abstracts in late-breaker sessions, at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., being held April 17 to 21, 2010.

The schedule and meeting location for the sessions, together with the abstract information and details on an educational session also featuring ARIAD, are listed below by program:

Ridaforolimus

Title: RAS signaling is the key factor determining differential response to PI3K and MAPK targeting compounds in a panel of breast cancer cell lines
Date & Time: Monday, April 19, 2010, 2:00 PM - 5:00 PM
Session Title: Cancer Genomics and Bioinformatics 2
Abstract: #1986
Presenter: Igor Feldman, Ph.D. (Merck)
Location: Exhibit Hall A-C, Poster Section 1

Title: PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical models
Date & Time: Tuesday, April 20, 2010, 9:00 AM - 12:00 PM
Session Title: Combinatorial Approaches to Therapy
Abstract: #3478
Presenter: Brian Haines, Ph.D. (Merck)
Location: Exhibit Hall A-C, Poster Section 21

Title: Mutual feedback activation of PI3K and MAPK pathways support combining inhibitors of the two pathways to enhance efficacy
Date & Time: Tuesday, April 20, 2010, 2:00 PM - 5:00 PM
Session Title: Therapeutics 2
Abstract: #4151
Presenter: Theresa Zhang, Ph.D. (Merck)
Location: Exhibit Hall A-C, Poster Section 11

Title: Combination of antiandrogens and PI3-kinase pathway inhibitors in a model of androgen-dependent prostate cancer
Date & Time: Tuesday, April 20, 2010, 2:00 PM - 5:00 PM
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Abstract: #LB-284
Presenter: Clay Efferson (Merck)
Location: Exhibit Hall A-C, Poster Section 39

AP24534

Title: Structural analysis of the inhibitory mechanism of AP24534, a pan-BCR-ABL inhibitor overriding the T315I gatekeeper mutation
Date & Time: Monday, April 19, 2010, 2:00 PM - 5:00 PM
Session Title: Structural Biology and Drug Design
Abstract: #2671
Presenter: Xiaotian Zhu, Ph.D. (ARIAD Pharmaceuticals)
Location: Exhibit Hall A-C, Poster Section 28

AP26113

Title: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)
Date & Time: Tuesday, April 20, 2010, 9:00 AM - 12:00 PM
Session Title: Receptor Tyrosine Kinase Inhibitors
Abstract: #3623
Presenter: Victor M. Rivera, Ph.D. (ARIAD Pharmaceuticals)
Location: Exhibit Hall A-C, Poster Section 26

Title: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066)
Date & Time: Tuesday, April 20, 2010, 2:00 PM - 5:00 PM
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Abstract: #LB-298
Presenter: Sen Zhang, Ph.D. (ARIAD Pharmaceuticals)
Location: Exhibit Hall A-C, Poster Section 39

Educational Session

Title: On the road from research to reality: Pharmaceutical product development concepts for potent compounds, including AP24534, a novel multi-targeted kinase inhibitor
Date & Time: Saturday, April 17, 2010 1:00 PM – 3:00 PM
Session Title: From Chemistry to the Clinic, Part 3: Chemical Development –Translating a Potent Agent into a Registered Product
Presenter: Christopher K. Murray, Ph.D. (ARIAD Pharmaceuticals)
Location: Room 147

About ARIAD

ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD’s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck. ARIAD’s second internally discovered product candidate, AP24534, is an investigational pan-BCR-ABL inhibitor completing Phase 1 clinical development in patients with hematological cancers, notably chronic myeloid leukemia. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com.



CONTACT:

ARIAD Pharmaceuticals, Inc.
Maria E. Cantor, 617-621-2208

KEYWORDS:   United States  North America  District of Columbia  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.